Sensory gating in patients with Alzheimer's disease and their biological children

American Journal of Alzheimer's Disease and other Dementias

Volumn 21, Issue 6, 2006, Pages 439-447

  Ally, Brandon A ^a,b   Jones, Gary E ^a,b   Cole, Jack A ^c   Budson, Andrew E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Alzhiemer's disease; At risk; P50; Sensory gating

Indexed keywords

ACETYLCHOLINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; EVOKED SOMATOSENSORY RESPONSE; FAMILY HISTORY; FEMALE; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; NEUROPHYSIOLOGY; PARASYMPATHETIC INNERVATION; RISK ASSESSMENT; SENSORY DYSFUNCTION;

EID: 33845960091     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317506292282     Document Type: Article

References (44)

1. Hebert LE, Seherr PA, Bienias JL, et al. Alzheimer's disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119-1122.
2. Solomon PH, Budson AE. Alzheimer's disease. Clin Symp. 2003;54:1-44.
3. Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimers disease? Pharmacogenomics J. In press.
4. Walker LC, Ibegbu CC, Todd CW, et al. Emerging prospects for the disease-modifying treatment of Alzheimers disease. Biochem Pharmacol. 2005;69:1001-1008.
5. Bäckman L, Jones S, Berger A, et al. Cognitive impairment in preclinical Alzheimers disease: a meta-analysis. Neuropsychology. 2005;19:520-531.
6. McCool MF, Varty GB, Del Vecchio HA, et al. Increased auditory startle response and reduced prepulse inhibition of startle in transgenic mice expressing a double mutant form of amyloid precursor protein. Brain Res. 2003;994:99-106.
7. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease-interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res. 2005;6-7:895-908.
8. Burghaus L, Schutz U, Krempel U, et al. Quantitative assessment of nicotinie acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res. 2000;76:385-388.
9. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlated of alteration in acetycholinesterase in Alzheimer's disease. Neurosci Lett. 2005;1-2:127-132.
10. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, et al. Cholinergic- serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia. 2005;43:442-449.
11. Cummings JL, Scheider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004;161:532-538.
12. Mega MS, Masterson DM, O'Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer's disease. Arch Neurol. 1999;56:1388-1393.
13. Minger SL, Esiri MM, McDonald B, et al. Cholinergic deficits contribute to behavioral disturbances in patients with dementia. Neurology. 2000;55:1460-1467.
14. Mesulam M, Shaw P, Mash D, et al. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol. 2004;55:815-828.
15. Herholtz K, Weisenbuch S, Kalbe E, et al. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport. 2005;16:1431-1434.
16. Pekkonen E, Jaaskelainen IP, Kaakkola S, et al. Cholinergic modulation of preattentive processing in aging. Neuroimage. 2005;27:387-392.
17. Grunwald T, Boutros NN, Pezar N, et al. Neuronal substrates of sensory gating within the human brain. Biol Psychiatry. 2003;53:511-519.
18. Jessen E, Kucharski C, Fries T, et al. Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am J Psychiatty. 2001;158:1319-1321.
19. Braff DE, Geyer MA. Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry. 1990;47:181-188.
20. Luntz-Leybman V, Bickford P, Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 1992;587:130-136.
21. Freedman R, Hall L, Adler M, et al. Evidence in post-mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38:22-33.
22. Cullum C, Harris J, Waldo M, et al. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res. 1993;10: 131-141.
23. Jaaskelainen IP, Hirvonen J, Huttunen J, et al. Scopolomine enhances middle-latency auditory evoked magnetic fields. Neurosci Lett. 1999;259:41-44.
24. Leonard S, Adams C, Breese CR, et al. Nicotinic receptor function in schizophrenia. Schizophr Bull. 1996;22: 431-445.
25. Freedman R, Adler LE, Myles-Worsley M, et al. Inhibitory gating of an evoked response to repeated auditory stimuli in schizophrenic and normal subjects: human recordings, computer simulation, and an animal model. Arch Gen Psychiatry. 1996;53:1114-1121.
26. Buchwald JS, Erwin RJ, Read S, et al. Midlatency auditory evoked responses: differential abnormality of P1 in Alzheimer's disease. Electroencephalogr Clin Neurophysiol. 1989;74:378-384.
27. Pekkonen E, Hirvonen J, Jaaskelainen IP, et al. Auditory sensory memory and the cholinergic system: implications for Alzheimer's disease. Neuroimage. 2001;14: 376-382.
28. Green JB, Flagg L, Freed DM, et al. The middle-latency auditory evoked potential may be abnormal in dementia. Neurology. 1992;42:1034-1036.
29. Green JB, Burba A, Freed DM, et al. The P1 component of the middle-latency auditory potential may differentiate a brainstem group of Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11:153-157.
30. Fein G, Biggins C, Van Dyke C. The auditory P50 response is normal in Alzheimer's disease when measured via a paired click paradigm. Electroencephalogr Clin Neurophysiol. 1994;92:536-545.
31. Golob EJ, Miranda GG, Johnson JK, et al. Sensory cortical interactions in aging, mild cognitive impairment, and Alzheimer's disease. Neurobiol Aging. 2001; 22:755-763.
32. Irimajiri R, Golob EJ, Starr A. Auditory brain-stem, middle- and long-latency evoked potentials in mild cognitive impairment. Clin Neurophysiol. 2005;116:1918-1929.
33. Devi G, Ottman R, Tang M, et al. Familial aggregation of Alzheimer's disease among whites, African Americans, and Caribbean Hispanics in northern Manhattan. Arch Neurol. 2000;57:72-77.
34. Reiman EM, Chen K, Alexander GE, et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's disease. Proc Natl Acad Sci U S A. 2004;101:284-289.
35. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
36. Yee CM, White PM. Experimental modification of P50 suppression. Psychophysiology. 2001;38:531-539.
37. Jerger K, Biggins C, Fein G. P50 suppression is not affected by attentional manipulations. Biol Psychiatry. 1992;31:365-377.
38. Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137-147.
39. Giannakopoulos P, Herrmann FR, Bussiere T, et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology, 2003;60:1495-1500.
40. Morris JC, Price AL. Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101-118.
41. Dekosky ST, Ikonomovic MD, Styren SD, et al. Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 2002;51:145-155.
42. Kordower JH, Chu Y, Stebbins GT, et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment. Ann Neurol. 2001;49: 202-213.
43. Mufson EJ, Chen EY, Cochran EJ, et al. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999;158:469-490.
44. Ally BA, Jones GE, Cole JA, et al. The P300 component in patients with Alzheimer's disease and their biological children. Biol Psychol. 2006;72:180-187.